Across 56 human clinical studies, the relationships between gut microbiota and microbial-derived polyphenol metabolites (MPMs) cluster around three compound classes: phenolic acids (20 studies), phytoestrogens (18 studies), and urolithins (17 studies). Specific bacterial taxa recurrently associate with particular metabolites — Gordonibacter with urolithin production, Alistipes with equol — though most studies relied on lower-resolution 16S rRNA sequencing (42 studies) rather than metagenomic shotgun sequencing (only 6), fundamentally limiting what can be inferred about microbial function rather than mere taxonomy.
This review crystallizes a problem health-science researchers have long suspected but rarely quantified: polyphenol bioactivity is not an intrinsic property of the food you eat — it's a property of your microbiome's capacity to process that food. The well-publicized benefits of resveratrol, flavanones, and flavan-3-ols (think red wine, citrus, green tea) rest on a metabolic transformation most people's guts may perform inconsistently or not at all. Equol production from soy isoflavones, for instance, occurs in only roughly 30–50% of Western adults. The clinical implication is significant: recommending polyphenol-rich foods as broadly health-promoting oversimplifies a deeply personalized biochemistry. As a scoping review, this paper maps terrain rather than testing causal hypotheses — it cannot tell us which interventions work or for whom. Its value lies in exposing how thin and methodologically inconsistent the evidence base actually is, making it a sobering, useful corrective rather than an actionable advance.